2016_Head & Neck COURSE BOOK

DAHANCA19 ‐ Acute morbidity Confluent mucositis

Grade 3‐4 in‐field reaction

Maximum difference at day14 after  end of RT: p<0.0001

zalutumumab

3+4 (%) 60

itis (%) 60

Control

40

40

al t m mab z u u u

ield grade

uent mucos

20

20

entage in-f 0

control

0

ntage confl

W1 W2 W3 W4 W5 End RT 14 day 2 month W1 W2 W3 W4 W5 End 2Wk 2Mo Maximum difference in week 5: p=0.001 Need for tube‐feeding at end of treatment:  No difference (50% vs. 50%)

Perc

Perce

W1 W2 W3 W4 W5 End RT 14 day 2 months W1 W2 W3 W4 W5 End 2Wk 2Mo

Eriksen, H&N Arizona 2014